Karo Pharma AB (publ)
Not enough financial coverage to compute a composite score for KARBF. This is typical for foreign-listed ADRs, recent IPOs, or thinly-covered small caps. Live quote, chart, and any available data still render below.
Companywww.karopharma.com
Karo Pharma AB (publ) develops and markets prescription drugs and over-the-counter products for pharmacies and retail sector in Sweden, Norway, Denmark, Finland, France, Germany, Italy, rest of Europe, the United States, and internationally. It offers skin health products under the Remescar, Locobase, Decubal, and indy beauty brand names; intimate health products under the Pevaryl, Multi Gyn, Asan, and Selexid brand names; and foot health products under the Pevaryl, CCS, Nailner, and wortie brands. The company also provides pain, cough, and cold products under the Paracet, Ibux, Mollipect, and Viruseptin brand names; prescription drugs under the Burinex, Centyl, Kaleorid, and Lithionit brands; and wellness products under the nutravita, Alpha Foods, Flux, Allévo, Dosett, Dax, and Lactocare brands.
- CEO
- Christoffer Lorenzen
- IPO
- 2013
- Employees
- 225
- HQ
- Stockholm, SE
Price Chart
Performance & Tape
- 52W High
- $5.71
- 52W Low
- $5.25
- 50D MA
- $5.25
- 200D MA
- $5.25
- Beta
- 0.00
- Avg Volume
- 0
Get TickerSpark's AI analysis on KARBF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our KARBF Coverage
We haven't published any research on KARBF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate KARBF Report →